Methyltransferase Inhibitors: Changing the Treatment Algorithm for Myelodysplastic Syndromes

National Comprehensive Cancer Network Practice Guidelines in Oncology V1.2004. Myelodysplastic syndromes. 10/31/2003 National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed September 7, 2004.

Silverman L.R. , Demakos E.P. , Peterson B.L. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20: 2429–2440.

Molldrem J.J. , Leifer E. , Baheci E. Antithymocyte globulin for treatment of bone marrow failure associated with myelodysplastic syndrome. Ann Intern Med. 2002; 137: 156–163.

Saunthararajah Y. , Nakamura R. , Nam J.M. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002; 100: 1570–1574.

Cutler C.S. , Lee S.J. , Greenberg P. A decision analysis of allogeneic bone marrow transplantation for myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579–585.